| Patents for C07D 295 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms (34,005) |
|---|
| 11/10/2009 | US7615550 Such as 1-(4-{[1-(1-methylethyl)-4-piperidinyl]oxy}phenyl)-4-{[4-(methylsulfonyl)phenyl]carbonyl}piperazine; neurodegenerative disorders including Alzheimer's disease; allergic rhinitis |
| 11/10/2009 | US7615549 Substituted pyrrolidinones, their manufacture and their use as medicaments |
| 11/10/2009 | CA2410862C Factor viia inhibitory (thio)urea derivatives, their preparation and their use |
| 11/05/2009 | WO2009134987A1 Difluoromethyl-containing macrocyclic compounds as hepatitis c virus inhibitors |
| 11/05/2009 | WO2009133179A2 Method for the production of halogen-substituted 2-(aminomethylidene)-3- oxobutyric acid esters |
| 11/05/2009 | WO2009132740A2 Reactive ionic liquids |
| 11/05/2009 | WO2009132453A1 Cyclylamine derivatives as calcium channel blockers |
| 11/05/2009 | WO2009132452A1 Diaryl-cyclylalkyl derivatives as calcium channel blockers |
| 11/05/2009 | US20090275664 Novel polyamine analog conjugates and quinone conjugates as therapies for cancers and prostate diseases |
| 11/05/2009 | US20090275556 Aryl sulfonamides useful as inhibitors of chemokine receptor activity |
| 11/05/2009 | US20090274972 Electrostatic-image-developing toner, method of producing the same, electrostatic image developer, image forming method and image forming apparatus |
| 11/05/2009 | US20090274656 Hepatitis c virus inhibitors |
| 11/05/2009 | CA2722704A1 Cyclylamine derivatives as calcium channel blockers |
| 11/04/2009 | EP1784388B1 Biphenyloxyacetic acid derivatives for the treatment of respiratory disease |
| 11/04/2009 | EP1553092B1 Aralkyl formyl-alkyl piperazine derivatives and their uses as cerebral nerve protective agent |
| 11/04/2009 | EP1339684B1 Mch antagonists and their use in the treatment of obesity |
| 11/04/2009 | CN101570517A 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives |
| 11/03/2009 | US7612206 Sigma-2 receptor radiotracers for imaging the proliferative status of solid tumors |
| 11/03/2009 | US7612122 Piperazino based photoinitiators |
| 11/03/2009 | US7612114 Selective estrogen receptor modulator |
| 11/03/2009 | US7612067 Imidazopyridazine compounds |
| 11/03/2009 | CA2443724C Novel, arylsusfonamide compounds for the treatment of obesity, type ii diabetes and cns-disorders |
| 11/03/2009 | CA2442423C Therapeutic drug for psychoneurotic disorders |
| 11/03/2009 | CA2420585C Amides of r-2-(aminoaryl)-propionic acids for use in the prevention of leucocyte activation |
| 11/03/2009 | CA2340670C An anthraquinone and its derivatives |
| 10/29/2009 | WO2009131189A1 Ketoxime ester compound and use thereof |
| 10/29/2009 | WO2009131065A1 Long-chain fatty acid elongation enzyme inhibitor comprising arylsulfonyl derivative as active ingredient |
| 10/29/2009 | WO2009130735A1 Fatty acid derivatives for oral administration endowed with high palatability |
| 10/29/2009 | WO2009101201A3 Mixtures of metal hydrides and ionic liquids and uses of such mixtures |
| 10/29/2009 | US20090270478 Ion channel modulating activity ii |
| 10/29/2009 | US20090270385 useful in treating vision defects, inflammatory bowel disease, alopecia, the stimulation of hair growth and the stimulation of the conversion of vellus hair to terminal hair |
| 10/29/2009 | US20090270365 such as N-(2,4-dimethyl-3-oxo-3,4-dihydro-2H-1,4-benzoxazin-6-yl)-2-(piperidin-1-ylmethyl)biphenyl-4-carboxamide, having vanilloid receptor 1 antagonistic activity, used as analgesics |
| 10/29/2009 | US20090270338 Diaryl-cyclylalkyl derivatives as calcium channel blockers |
| 10/29/2009 | US20090269673 Process for the preparation of compounds containing perfluoroalkanesulfonic acid groups |
| 10/29/2009 | CA2722075A1 Long-chain fatty acyl elongase inhibitor comprising arylsulfonyl derivative as active ingredient |
| 10/29/2009 | CA2721756A1 Fatty acid derivatives for oral administration endowed with high palatability |
| 10/29/2009 | CA2720818A1 Substituted phenoxybenzamides |
| 10/28/2009 | EP1709024B1 Piperazino sensitisers |
| 10/28/2009 | EP1692098B1 Alpha-ketoamide derivative, and production method and use thereof |
| 10/28/2009 | CN101565410A Preparation method for 1-piperazine acetyl pyrrolidine |
| 10/28/2009 | CN101565409A Piperazidine or homopiperazine oxalyl hydrazine class compound, preparation and use thereof |
| 10/28/2009 | CN100554257C 1-(4-benzyl-piperazin-1-yl)-3-phenyl-propenone derivatives |
| 10/28/2009 | CN100554256C Quaternary ammonium salt, electrolyte, and electrochemical device |
| 10/28/2009 | CN100554234C Clear photopolymerizable systems for the preparation of high thickness coatings |
| 10/27/2009 | US7608739 2,3-Dihydrooxadiazoles such as 3-acetyl-5-(2,5-difluorophenyl)-2-phenyl-2,3-dihydro-1,3,4-oxadiazole and 3-[3-acetyl-5-(2,5-difluorophenyl)-2-phenyl-2,3-dihydro-1,3,4-oxadiazol-2-yl]-N,N-dimethylpropan-1-amine that are useful for treating cancer |
| 10/27/2009 | US7608632 Sulfonamide inhibitors of aspartyl protease |
| 10/27/2009 | US7608623 N- alpha -(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyamidino-(L)-phenylalanine-4-ethoxycarbonylpiperazinium hydrogen sulfate; N- alpha -(2,4,6-triisopropylphenylsulfonyl)-3-hydroxyguanidino-(L)-phenylalanine-4-ethoxycarbonylpiperazide; urokinase plasminogen activator inhibitor; anticarcinogenic agent |
| 10/27/2009 | US7608617 N,N-alkylene-6-(piperidin-1-ylalkoxy)naphthalene-2-carboxamide derivatives, e.g., piperidin-1-yl-[6-(3-piperidin-1-yl-propoxy)-naphthalen-2-yl]-methanone and 3,4-dihydro-1H-isoquinolin-2-yl)-[6-(3-piperidin-1-yl-propoxy)-naphthalen-2-yl]-methanone; especially for treating obesity |
| 10/27/2009 | US7608611 18,21-didehydro-18,21-dideoxo-18,21-dihydroxy-geldanamycin derivatives as anticarcinogenic agent; with a metal chelating agent |
| 10/27/2009 | CA2466724C Benzamide and heteroarylamide as p2x7 receptor antagonists |
| 10/27/2009 | CA2432713C Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
| 10/27/2009 | CA2359454C ((aminoiminomethyl) amino) alkanecarboxamides and their applications in therapy |
| 10/27/2009 | CA2318145C Sulfonylamino derivatives which inhibit matrix-degrading metalloproteinases |
| 10/22/2009 | WO2009128521A1 Cysteine protease inhibitor |
| 10/22/2009 | WO2009127723A1 New arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments |
| 10/22/2009 | US20090264651 reduce the chelation and other negative interactions of the buffer and the system to be buffered; zwitterionic buffers improve yield by allowing a greater range of stability |
| 10/22/2009 | US20090264435 Novel Aryl- and Heteroarylpiperazines |
| 10/22/2009 | US20090264417 N-sulfonyl heterocyclic ring such as piperazine connected via sulfonyl group to another fused heterocyclic ring such as benzothiophene or indoline; peroxisome proliferator-activated receptor (PPAR); obesity, diabetes, hyperinsulinemia, metabolic syndrome X, polycystic ovary syndrome |
| 10/22/2009 | CA2721785A1 New arylsulphonylglycine derivatives, the preparation thereof and their use as medicaments |
| 10/21/2009 | EP1979320B1 PIPERAZINES AND PIPERIDINES AS mGluR5 POTENTIATORS |
| 10/21/2009 | EP1608374B9 2-phenoxy- and 2-phenylsulfomamide derivatives with ccr3 antagonistic activity for the treatment of asthma and other inflammatory or immunological disorders |
| 10/21/2009 | CN101563351A Substituted pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors |
| 10/21/2009 | CN101563332A Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments |
| 10/21/2009 | CN101560196A High-purity ranolazine and preparation method thereof |
| 10/21/2009 | CN101560175A Thiourea derivatives and preparation method and use thereof |
| 10/21/2009 | CN100551370C Use of Ranolazine in preparing pharmaceutical composition for treating diabetes |
| 10/20/2009 | US7605280 1,5-Bis-((2-dimethylamino-N-oxide)ethyl)amino)-4,8-dihydroxyanthracene-9,10-dione; DRAQ5 dyes;analyzing cells/biological material and detecting emitted fluorescence signal; cell permeant DNA-interactive agents providing a fluorescence signature into the infra red spectra; red-line emitting lasers |
| 10/20/2009 | US7605271 Superhigh purity ionic liquid |
| 10/20/2009 | US7605261 Urea derivatives, method for preparing same, use thereof as medicines, pharmaceutical compositions and novel use |
| 10/20/2009 | US7605260 Process for producing imide compound |
| 10/20/2009 | US7605259 Structurally rigid dopamine d3 receptor selective ligands and process for making them |
| 10/20/2009 | US7605176 β-ketoamide compounds with MCH antagonistic activity |
| 10/20/2009 | US7605163 Benzoyl-piperazine derivatives |
| 10/20/2009 | US7605161 Pyridyl derivatives and their use as therapeutic agents |
| 10/20/2009 | CA2585898C Use of (2s,3s,5s)-5-(n-(n-((n-methyl-n-((2-isopropyl-4-thaizolyl)methyl)amino)-carbonyl)valinyl)amino)-2-(n-((5-thiazolyl)methoxycarbonyl)amino)-1,6-diphenyl-3-hydroxyhexane in combination with another protease inhibitor for treating hiv infection |
| 10/20/2009 | CA2380986C Carboxylic acid amides, the preparation thereof and their use as pharmaceutical compositions |
| 10/20/2009 | CA2245066C Zinc-phthalocyanines and corresponding conjugates, their preparation and use in photodynamic therapy and as diagnostic agents |
| 10/15/2009 | WO2009125861A1 Cysteine protease inhibitor |
| 10/15/2009 | WO2009125853A1 Homocysteine synthase inhibitor |
| 10/15/2009 | WO2009125851A1 Method for detection of effectiveness of phenylalanine derivative-type compound in diabetes patient |
| 10/15/2009 | WO2009125606A1 Pai-1 inhibitor |
| 10/15/2009 | WO2009124853A1 New ruthenium complexes as catalysts for metathesis reactions |
| 10/15/2009 | US20090258884 Substituted amides |
| 10/15/2009 | US20090258871 Aza-Substituted Spiro Derivatives |
| 10/15/2009 | DE102008045937A1 Verbindung aus einem Metallion und einem Markierungsvorläufer und Verwendung der Verbindung Compound of a metal ion and a labeling precursor and use of the compound |
| 10/15/2009 | CA2725425A1 Homocysteine synthase inhibitor |
| 10/15/2009 | CA2720530A1 Sulfonamides |
| 10/15/2009 | CA2720096A1 Pai-1 inhibitor |
| 10/15/2009 | CA2719531A1 New ruthenium complexes as catalysts for metathesis reactions |
| 10/14/2009 | EP1877367B1 Acetylene derivatives |
| 10/14/2009 | EP1658267B1 Inhibitors of cathepsin s |
| 10/14/2009 | CN101555235A Manufacture process of piperazine ferulate |
| 10/14/2009 | CN100548999C Process for preparing N-formyl morpholine |
| 10/14/2009 | CN100548998C Cinepazide maleate crystal form and its preparation method |
| 10/14/2009 | CN100548997C Method for separating N-ethylpiperazine-ethanolamine azeotropic mixture by azeotropic rectifying intermittent operation |
| 10/14/2009 | CN100548955C New photoinitiators |
| 10/14/2009 | CN100548477C Catalyst required for coproducing N-methyl morpholine and morpholine |
| 10/14/2009 | CN100548291C MCH antagonists for the treatment of obesity |
| 10/13/2009 | US7601874 Antiinflammatory agents; antiarthritic agents; brain disorders; multiple sclerosis; gout; inflammatory bowel disorders; gastrointestinal disorders; psoriasis; antiallergens; autoimmune disease |
| 10/13/2009 | US7601868 Such as 4-(cyclopropylmethoxy)-N-(2-{4-[1-(1-pyrrolidinyl)ethyl]phenyl}ethyl)benzamide having melanin-concentrating hormone antagonistic action, for prophylaxis and/or treatment of obesity |